Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
"The proposed divestiture of Udenyca represents the successful execution of our strategy to focus R&D and commercial resources on Coherus' innovative immuno-oncology portfolio and to strengthen our financial position," said On Tuesday, Coherus BioSciences, Inc. (NASDAQ:CHRS) entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca (pegfilgrastim-cbqv) franchise for up to $558.4 million.
在周二，coherus biosciences, inc.（纳斯达克：CHRS）与Intas Pharmaceuticals Ltd达成了一项资产购买协议，出售Udenyca（pegfilgrastim-cbqv）业务，金额高达55840万。
The deal consideration includes an upfront payment of $483.4 million, to be adjusted for inventory at the close, and $75 million in potential net sales milestone payments.
该交易的对价包括48340万的预付款，交易结束时将根据库存进行调整，以及7500万的潜在净销售里程碑付款。
Coherus plans to use a portion of the transaction proceeds to fully repay the company's $230 million in existing convertible notes due April 2026 and $49.1 million to buy out certain royalty obligations related to Udenyca.
Coherus计划将交易收益的一部分用于全额偿还公司23000万的现有可转换债券（到期日为2026年4月）和4910万用于买断与Udenyca相关的某些特许权使用费义务。
"The proposed divestiture of Udenyca represents the successful execution of our strategy to focus R&D and commercial resources on Coherus' innovative immuno-oncology portfolio and to strengthen our financial position," said Denny Lanfear, Coherus chairman and chief executive officer.
coherus董事长兼首席执行官Denny Lanfear表示：“拟议的Udenyca出售代表了我们成功实施战略的结果，旨在将研发和商业资源聚焦于coherus的创新免疫肿瘤组合，并增强我们的财务状况。”
The proposed transaction is expected to close by the end of Q1 2025.
预计交易将在2025年第一季度末完成。
Coherus intends to strengthen and sharpen its focus on advancing its immuno-oncology portfolio in combination with Loqtorzi, a next-generation, differentiated PD-1 marketed in the U.S. in two indications.
Coherus打算加强并明确关注推进其免疫肿瘤组合，与Loqtorzi联合，这是一种在美国上市的下一代、差异化的PD-1，有两个适应症。
Additional partnerships evaluating Loqtorzi with other cancer agents are planned for 2025.
计划在2025年与其他癌症药物共同评估Loqtorzi的额外合作伙伴关系。
The company plans to initiate a Phase 2 trial of casdozokitug/toripalimab/bevacizumab in first-line (1L) hepatocellular carcinoma (HCC) in Q4 2024, with final data from Phase 2 trial of casdozokitug/atezolizumab/bevacizumab in 1L HCC in Q1 2025, and data from its Phase 1 study of casdozokitug/toripalimab in second to fourth line (2-4L) non-small cell lung cancer (NSCLC) in 1H 2025.
该公司计划在2024年第四季度启动casdozokitug/toripalimab/bevacizumab在一线（1L）肝细胞癌（HCC）中的第二阶段试验，在2025年第一季度获得casdozokitug/atezolizumab/bevacizumab在1L HCC的第二阶段试验的最终数据，以及在2025年上半年获得casdozokitug/toripalimab在第二到第四线（2-4L）非小细胞肺癌（NSCLC）中的第一阶段研究数据。
Coherus plans to:
Coherus计划：
- Report Phase 1 monotherapy biopsy data and CHS-114/toripalimab combination safety data in head and neck squamous cell carcinoma (HNSCC) in 1H 2025.
- Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L head and neck squamous cell carcinoma in Q1 2025, with a first data readout expected in Q2 2026.
- Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer in Q1 2025, with a first data readout expected in Q2 2026.
- 在2025年上半年报告单药生物活检数据以及CHS-114/托瑞帕利组合在头颈部鳞状细胞癌（HNSCC）中的安全性数据。
- 在2025年第一季度启动一项针对2L头颈部鳞状细胞癌的10亿CHS-114/托瑞帕利组合剂量优化研究，预计在2026年第二季度进行首次数据读取。
- 在2025年第一季度启动一项针对2L胃癌的10亿CHS-114/托瑞帕利组合剂量优化研究，预计在2026年第二季度进行首次数据读取。
Earlier this year, Coherus BioSciences divested its Cimerli ophthalmology franchise to Sandoz Group AG (OTC:SDZNY) (OTC:SDZXF) for $170 million plus an additional amount for inventory.
今年早些时候，Coherus Biosciences将其Cimerli眼科医疗业务出售给Sandoz Group AG（场外交易:SDZNY）（场外交易:SDZXF），交易金额为17000万美元，加上额外的库存金额。
Price Action: CHRS stock is up 41.6% at $1.94 at last check Tuesday.
价格动态：截至周二最后检查，CHRS股票上涨41.6%，报1.94美元。
- Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
- Merus获得癌症潜在药物Zenocutuzumab的美国商业化权利，分析师强调Merus的产品线
Photo: Shutterstock
Photo: shutterstock
